Clinical Trial Update: ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial ROMAN assessing GC4419 for radiation-induced oral mucositis in head and neck cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• GC4419

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: Oral Mucositis | Phase 3 | Status: COMPLETED | Results posted: 2023-04-13